Navigation Links
Chem Rx Corporation Reports First Quarter 2008 Financial Results
Date:5/30/2008

ntinue to execute on key growth initiatives, as evidenced by the 20.2% increase in net sales. Importantly, our first quarter increase in net sales was achieved through organic growth, driven by our strong reputation and high quality of service. We continue to be excited about our opportunities in Florida and have recently received a commitment for 1,000 new beds beginning in the fourth quarter of 2008."

Steven C. Silva, President and Chief Operating Officer, stated, "In the first quarter of 2008, our gross margin dollars increased by $3.9 million, driven primarily by our growth in beds and improved efficiencies. Our SG&A expenses rose both in dollars and as a percentage of sales due to increased professional fees associated primarily with the cost of being a public company and higher delivery costs. In addition, we incurred greater administrative costs associated with the opening of our Deerfield Beach, Florida facility, which commenced operations on April 1st of this year."

Recent Corporate Developments

On April 1, 2008, the Company's pharmacy operations center in Deerfield Beach, Florida commenced operations.

On April 18, 2008, the Company changed its stock symbol to CHRX from PMQC.

On April 30, 2008, the Company engaged Grant Thornton LLP to serve as the Company's independent registered public accounting firm.

Conference Call

To participate in the conference call on June 3, 2008 at 8:30 am ET, please dial 1-877-407-0784 (USA) or 1-201-689-8560 (international). A web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.chemrx.net. In addition, a dial-up replay of the conference call will be available beginning June 3, 2008 at approximately 11:30 a.m. ET and will remain available until June 10, 2008. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the
'/>"/>

SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genaera Corporations 2008 Annual Stockholder Meeting Results
2. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
3. AMERIGROUP Corporation to Present at the Goldman Sachs 29th Annual Global Healthcare Conference on June 11
4. CuraGen Corporation Regains NASDAQ Listing Compliance
5. Kewaunee Scientific Corporation Increases Quarterly Dividend
6. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
7. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
8. GenoLogics Releases BioVault Biospecimen Management Software in Partnership With GenVault Corporation
9. Linkwell Corporation Runs 24/7 Disinfectant Operations to Support Chinas Earthquake Relief Efforts
10. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
11. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...compliance and ethics online forum , , MINN...iety of Corporate Compliance and Ethics (SCCE) and...ounced today the associations are making their Soc...ethics professionals beginning today, December 4, ...es and participate in the online discussions, comp...
(Date:12/4/2008)... Agree the Shortage Must Be Addressed , , C...dent-elect Barack Obama and the incoming 111th Con...ly complicating the process of achieving effective...ons (ACS) has released a comprehensive policy stat... ACS calls on policymakers to support a reform app...
(Date:12/4/2008)...sica Biel and family today unveiled,the details o...ildrens,Hospital Los Angeles. The party, made pos...uded numerous recording artists and gifts from lea...it to children at the hospital. , "The kids...ing some of the,great artists we had at the hospi...
(Date:12/4/2008)...or sickle cell disease and thalassemia , ... have identified a gene mutation that inhibits the...e-threatening anemias -- sickle cell disease and t... to new treatments that could restore some hemoglo...eases into manageable chronic conditions. , "We...
Breaking Medicine News(10 mins):Health News:SCCE and HCCA Social Network Now Open to All Compliance and Ethics Professionals 2Health News:SCCE and HCCA Social Network Now Open to All Compliance and Ethics Professionals 3Health News:American College of Surgeons Issues New Health Care Reform Agenda, Emphasizes Need to Address Access, Surgical Workforce Shortage 2Health News:American College of Surgeons Issues New Health Care Reform Agenda, Emphasizes Need to Address Access, Surgical Workforce Shortage 3Health News:American College of Surgeons Issues New Health Care Reform Agenda, Emphasizes Need to Address Access, Surgical Workforce Shortage 4Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2Health News:Gene Behind Childhood Anemias Found 2Health News:Gene Behind Childhood Anemias Found 3
...ork is very near to achieving one of today’s Scien...est possible health conditions.// As well as from...s of Seville, Oviedo, Saragossa, Barcelona and Reu...ding that the consumption of melatonin – a natural...
...mmonest medical disorder in pregnancy, adversely a...ral national programmes targeted at control and tr...s not been as anticipated, since the majority of w...status and anemia in pregnancy have consequences t...
...ched a seven-day camp in this Taj Mahal city, sayi...other licentious activities.// Ram Dev, who enjoys...pposed to sex education being given to the young. ... disciplined lifestyle is what we need (for) the y...
...healthcare inequalities may have the most signific...orectal cancer (CRC) between African// Americans a... in the June 1, 2007 issue of CANCER, a peer-revie...a-analysis of data from published studies demonstr...
Other Medicine News:Health News:High Melatonin can Help Delay Ageing 2Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2
(Date:12/3/2008)...Dec. 3 Wyeth Pharmaceuti...ed today that it has submitted a,marketing author...s Agency,(EMEA) for approval to market its invest...e (PCV13) for infants and young children. Wyeth i...umococcal disease (PD) caused by the 13,serotypes...
(Date:12/3/2008)...ec. 3 Isis Pharmaceutica...ncoGenex Pharmaceuticals, Inc.,provided positive ...l trial of,OGX-011 in combination with docetaxel ...cetaxel and prednisone alone ("the control arm") f...sistant prostate cancer. The current 10.6,month ...
(Date:12/3/2008)...PRNewswire-FirstCall/ -- Vical Incorporated,(Nasd... letter of intent with EIP,Eczacibasi Ilac Pazarl...any,s,Allovectin-7(R) immunotherapeutic product c...rthern Cyprus. EIP has agreed to obtain the necess... pay Vical upfront and milestone payments,plus a ...
(Date:12/2/2008)...Newswire-USNewswire/ -- Breast-specific gamma imag...rs not found on mammograms or by,clinical exam, a...meeting of,the Radiological Society of North Amer...ifficult to detect breast cancer-invasive,lobular..., professor of,radiology and director of the Brea...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Debiopharm and EPFL Establish an Oncology Chair 3548 1Debiopharm and EPFL Establish an Oncology Chair 3548 2Joslin study finds restricting insulin doses increases mortality risk 12835 1Joslin study finds restricting insulin doses increases mortality risk 12835 2Joslin study finds restricting insulin doses increases mortality risk 12835 3Testimony to Congress Denounces FDA Reliance on Self Policing 12832 1Testimony to Congress Denounces FDA Reliance on Self Policing 12832 2Michael Moore Defends 9 11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 12829 1Michael Moore Defends 9 11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 12829 2
...r-Causing Virus,Types 16 & 18 That Are At Leas... CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase ... a three-dose regimen, 100,percent of women up to ...ervical cancer candidate vaccine had antibodies pr...uman papillomavirus,types, 16 and 18. These data i...
...- Elixir,Pharmaceuticals, Inc., announced today ne...s a potential method for regulating,metabolism, de...he,data were presented in poster sessions during E...g, being held in Toronto,Canada. Elixir is focuse... metabolic disease, as well as prevent age-related...
Other Medicine Technology:Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility.
ADVIA Centaur delivers a new level of immunodiagnostic productivity. It provides the flexibility to integrate with any laboratory automation system, now and in the future. Most importantly, it offers
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry.
With an intuitive operator interface, enhanced sample handling and innovative menu, the state-of-the-art Access 2 system delivers new levels of laboratory efficiency, standardization and cost effecti
Medicine Products: